The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy
Open accessAbstract
Purpose: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia with a broad spectrum of clinical manifestations and outcomes in children. The somatic BRAF V600E mutation occurs frequently, but clinical significance remains to be determined. Patients and Methods: BRAF V600E mutation was investigated in a French LCH cohort. We analyzed associations between mutation status and clinical presentation, extent of disease, reactivation rate, response to therapy, and long-term permanent sequelae. Results: Among 315 patients with successfully determined BRAF status, 173 (54.6%) carried a BRAF V600E mutation. Patients with BRAF V600E manifested more severe disease than did those with wild-type BRAF. Patients with BRAF V600E comprised 87.8% of patients (43 of 49) with multisystem LCH with risk organ involvement (liver, spleen, hematology), 68.6% of patients (35 of 51) with multisystem LCH without risk organ involvement, 43.9% of patients (86 of 196) with single-system LCH, and 42.1% of patients (8 of 19) with lung-involved LCH (P < .001). BRAF V600E mutation was also associated with organ involvement that could lead to permanent, irreversible damage, such as neurologic (75%) and pituitary (72.9%) injuries. Compared with patients with wild-type BRAF, patients with BRAF V600E more commonly displayed resistance to combined vinblastine and corticosteroid therapy (21.9% v 3.3%; P = .001), showed a higher reactivation rate (5-year reactivation rate, 42.8% v 28.1%; P = .006), and had more permanent, long-term consequences from disease or treatment (27.9% v 12.6%; P = .001). Conclusion: In children with LCH, BRAF V600E mutation was associated with high-risk features, permanent injury, and poor short-term response to chemotherapy. Further population-based studies should be undertaken to confirm our observations and to assess the impact of BRAF inhibitors for this subgroup of patients who may benefit from targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Henter, J., Horne, A., Aricó, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K., Webb, D., Winiarski, J., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21039 · Cited by 5,386
Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very, G., Vergilio, J.-A., Degar, B. A., MacConaill, L. E., Brandner, B., Calicchio, M. L., Kuo, F. C., Ligon, A. H., Stevenson, K. E., Kehoe, S. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279083 · Cited by 1,243
Haroche, J., Charlotte, F., Arnaud, L., von Deimling, A., Hélias-Rodzewicz, Z., Hervier, B., Cohen-Aubart, F., Launay, D., Lesot, A., Mokhtari, K., et al. (2012) · Blood · doi:10.1182/blood-2012-05-430140 · Cited by 696
Self-citationHaupt, R., Minkov, M., Astigarraga, I., Schäfer, E., Nanduri, V., Jubran, R., Egeler, R. M., Janka, G., Micic, D., Rodriguez‐Galindo, C., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24367 · Cited by 692
Self-citationQuantitative and sensitive detection of rare mutations using droplet-based microfluidics
Pekin, D., Skhiri, Y., Baret, J.-C., Le Corre, D., Mazutis, L., Ben Salem, C., Millot, F., El Harrak, A., Hutchison, J. B., Larson, J. W., et al. (2011) · Lab on a Chip · doi:10.1039/c1lc20128j · Cited by 540
Self-citationHaroche, J., Cohen-Aubart, F., Emile, J.-F., Arnaud, L., Maksud, P., Charlotte, F., Cluzel, P., Drier, A., Hervier, B., Benameur, N., et al. (2013) · Blood · doi:10.1182/blood-2012-07-446286 · Cited by 537
Self-citationBerres, M.-L., Lim, K. P. H., Peters, T., Price, J., Takizawa, H., Salmon, H., Idoyaga, J., Ruzo, A., Lupo, P. J., Hicks, M. J., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130977 · Cited by 442
Chakraborty, R., Hampton, O. A., Shen, X., Simko, S. J., Shih, A., Abhyankar, H., Lim, K. P. H., Covington, K. R., Trevino, L., Dewal, N., et al. (2014) · Blood · doi:10.1182/blood-2014-05-577825 · Cited by 431
High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis
Brown, N. A., Furtado, L. V., Betz, B. L., Kiel, M. J., Weigelin, H. C., Lim, M. S., & Elenitoba-Johnson, K. S. J. (2014) · Blood · doi:10.1182/blood-2014-05-577361 · Cited by 369
Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004
Guyot‐Goubin, A., Donadieu, J., Barkaoui, M., Bellec, S., Thomas, C., & Clavel, J. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21498 · Cited by 351
Self-citation
Cited by
Rodriguez-Galindo, C., & Allen, C. E. (2020) · Blood · doi:10.1182/blood.2019000934 · Cited by 361
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease
Mass, E., Jacome-Galarza, C. E., Blank, T., Lazarov, T., Durham, B. H., Ozkaya, N., Pastore, A., Schwabenland, M., Chung, Y. R., Rosenblum, M. K., et al. (2017) · Nature · doi:10.1038/nature23672 · Cited by 210
Self-citation
Metadata
- Authors
- Héritier, S., Emile, J.-F., Barkaoui, M.-A., Thomas, C., Fraitag, S., Boudjemaa, S., Renaud, F., Moreau, A., Peuchmaur, M., Chassagne-Clément, C., Dijoud, F., Rigau, V., Moshous, D., Lambilliotte, A., Mazingue, F., Kebaili, K., Miron, J., Jeziorski, E., Plat, G., Aladjidi, N., Ferster, A., Pacquement, H., Galambrun, C., Brugières, L., Leverger, G., Mansuy, L., Paillard, C., Deville, A., Armari-Alla, C., Lutun, A., Gillibert-Yvert, M., Stephan, J.-L., Cohen-Aubart, F., Haroche, J., Pellier, I., Millot, F., Lescoeur, B., Gandemer, V., Bodemer, C., Lacave, R., Hélias-Rodzewicz, Z., Taly, V., Geissmann, F., & Donadieu, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-09-01
- Volume
- 34
- Issue
- 25
- Pages
- 3023-3030
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2474782031
- Cited by
- 342
- References
- 22
- FWCI
- 18.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. https://app.cochat.ai/papers/10.1200/jco.2015.65.9508
- The paper
- Héritier, S., Emile, J.-F., Barkaoui, M.-A., Thomas, C., Fraitag, S., Boudjemaa, S., Renaud, F., Moreau, A., Peuchmaur, M., Chassagne-Clément, C., Dijoud, F., Rigau, V., Moshous, D., Lambilliotte, A., Mazingue, F., Kebaili, K., Miron, J., Jeziorski, E., Plat, G., . . . Donadieu, J. (2016). BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.65.9508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.